A prospective randomized controlled clinical trial of zoledronic acid for bone metastases

American Journal of Hospice and Palliative Medicine

Volumn 23, Issue 1, 2006, Pages 41-50

  Mystakidou, Kyriaki ^a   Katsouda, Emmanuela ^a   Parpa, Efi ^a   Kouskouni, Evangelia ^a   Chondros, Costas ^a   Tsiatas, Marinos L ^a   Galanos, Antonis ^a   Vlahos, Lambros ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone metastases; Mobility status; Palliative; Zoledronic acid

Indexed keywords

EID: 31644449364     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910602300107     Document Type: Article

References (30)

1. Francis MD, Russell RG, Fleisch H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969; 165(899): 1264-1266.
2. Fleisch H, Russell RG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969; 165(899): 1262-1264.
3. Jung A, Bisaz S, Fleisch H: The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973; 11(4): 269-280.
4. Lipton A: Bisphosphonates and breast carcinoma. Cancer. 1997; 80(8 Suppl): 1668-73.
5. Body JJ: Bisphosphonates. Eur J Cancer. 1998; 34(2): 263-269.
6. Masarachia P, Weinreb M, Balena R, et al.: Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 1996; 19(3): 281-290.
7. Jung A, Mermillod B, Barras C, et al.: Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. Cancer Res. 1981; 41(8): 3233-3237.
8. Martodam RR, Thornton KS, Sica DA, et al.: The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int. 1983; 35(4-5): 512-519.
9. Sasaki A, et al.: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995; 55(16): 3551-3557.
10. Wood J, Bonjean K, Ruetz S, et al.: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302(3): 1055-1061.
11. Jagdev SP, Coleman RE, Shipman CM, et al.: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer. 2001; 84(8): 1126-1134.
12. Bezzi M, Hasmim M, Bieler G, et al.: Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem. 2003; 278(44): 43603-43614.
13. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004; 114(5): 623-633.
14. Vincenzi B, Santini D, Dicuonzo G, et al.: Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005; 25(3): 144-151.
15. Yaccoby S, Pearse RN, Johnson CL, et al.: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002; 116(2): 278-290.
16. Boissier S, Ferreras M, Peyruchaud O, et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000; 60(11): 2949-2954.
17. Peyruchaud O, Winding B, Pecheur I, et al.: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001; 16(11): 2027-2034.
18. Corey E, Brown LG, Quinn JE, et al.: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003; 9(1): 295-306.
19. Lipton A: Toward new horizons: The future of bisphosphonate therapy. Oncologist. 2004; 9(Suppl4): 38-47.
20. Coleman RE: Bisphosphonates: Clinical experience. Oncologist. 2004; 9(Suppl4): 14-27.
21. Green JR: Bisphosphonates: Preclinical review. Oncologist. 2004; 9(Suppl4): 3-13.
22. Mystakidou K, Katsouda E, Stathopoulou E, et al.: Approaches to managing bone metastases from breast cancer: The role of bisphosphonates. Cancer Treat Rev. 2005; 31(4): 303-311.
23. Rosen HN, Moses AC, Garber J, et al.: Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000; 66(2): 100-103.
24. Clezardin P: The antitumor potential of bisphosphonates. Semin Oncol. 2002; 29(6): 33-42.
25. Lipton A, Theriault RL, Hortobagyi GN, et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long-term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88(5): 1082-1090.
26. Lipton A, Zheng M, and Seaman J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003; 98(5): 962-969.
27. Rosen LS, Gordon DH, Dugan W Jr, et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004; 100(1): 36-43.
28. Mystakidou K, Katsouda E, Parpa E, et al.: Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol. 2005; 22(2): 195-202.
29. Cameron D: Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast. 2003; 12(Suppl2); S22-S29.
30. Berenson JR: Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005; 10(1): 52-62.